Sagimet Biosciences (NASDAQ:SGMT) Director George Kemble Sells 20,206 Shares of Stock

Sagimet Biosciences Inc. (NASDAQ:SGMT) Director George Kemble sold 20,206 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total transaction of $201,049.70. Following the completion of the sale, the director directly owned 62,161 shares in the company, valued at $618,501.95. This represents a 24.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

George Kemble also recently made the following trade(s):

• On Monday, July 20th, George Kemble sold 18,844 shares of Sagimet Biosciences stock. The stock was sold at an average price of $7.46, for a total value of $140,576.24.

Sagimet Biosciences Price Performance

SGMT opened at $9.39 on Thursday. The company has a market capitalization of $305.93 million, a price-to-earnings ratio of -7.34 and a beta of 3.37. The business’s 50-day moving average price is $7.39 and its two-hundred day moving average price is $6.52. Sagimet Biosciences Inc. has a 1 year low of $4.50 and a 1 year high of $10.06.

Sagimet Biosciences (NASDAQ:SGMT) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Sell-side analysts anticipate that Sagimet Biosciences Inc. will post -1.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on SGMT. Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Friday, July 17th. Guggenheim dropped their target price on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Oppenheimer reissued an “outperform” rating on shares of Sagimet Biosciences in a research report on Friday, May 1st. Citizens Jmp lowered their price target on Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating on the stock in a research report on Tuesday, May 19th. Finally, Canaccord Genuity Group upped their price objective on Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $26.33.

Sagimet Biosciences News Summary

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: Canaccord raises price target: Canaccord Genuity lifted its target for Sagimet from $49 to $56 and maintained a “buy” rating, implying substantial potential upside from recent trading levels. The upgrade reflects a bullish view of the company’s development prospects. Benzinga analyst price target report
• Positive Sentiment: Progress on denifanstat: Wedbush Securities said Sagimet is making “good progress” toward bringing denifanstat to U.S. patients. Positive commentary on the company’s lead drug candidate could support sentiment because future valuation depends heavily on clinical and regulatory execution. Sagimet making progress on denifanstat
• Neutral Sentiment: Short-interest data appears unreliable: Reported short interest was zero shares, unchanged from the prior period, with a zero days-to-cover ratio. Because the figures include an undefined percentage change and may reflect incomplete reporting, they provide little meaningful insight into trading pressure.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Sagimet reported a second-quarter 2026 loss of $0.26 per share, compared with analysts’ expectation of a $0.25 loss. The modest earnings miss reinforces that the company remains loss-making while it advances its pipeline. Sagimet second-quarter 2026 results
• Negative Sentiment: Director reduced holdings: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. While insider sales can be routine, the transaction may weigh on sentiment because it signals reduced personal exposure by a company director.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Sagimet Biosciences by 0.6% in the second quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock valued at $2,023,000 after purchasing an additional 1,600 shares during the period. Landscape Capital Management L.L.C. boosted its holdings in shares of Sagimet Biosciences by 14.1% during the 4th quarter. Landscape Capital Management L.L.C. now owns 25,901 shares of the company’s stock worth $153,000 after buying an additional 3,198 shares during the period. HighTower Advisors LLC grew its stake in Sagimet Biosciences by 10.1% in the 4th quarter. HighTower Advisors LLC now owns 37,189 shares of the company’s stock valued at $220,000 after buying an additional 3,408 shares during the last quarter. American Century Companies Inc. grew its stake in Sagimet Biosciences by 8.9% in the 2nd quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock valued at $322,000 after buying an additional 3,454 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in Sagimet Biosciences by 819.2% in the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after acquiring an additional 4,391 shares during the period. 87.86% of the stock is currently owned by institutional investors.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.